CVS Health Crushes Q3: $2.09 EPS Smashes Estimates, Guidance Raised

The short answer: CVS Health just delivered one of the biggest earnings beats of the season. On Wednesday morning, November 4, 2026, the health care giant reported third-quarter revenue of $108.4 billion and adjusted earnings of $2.09 per share — crushing Wall Street's $1.65 estimate — then raised its full-year guidance across the board.

What happened

CVS Health reported results for the quarter ended September 30, 2026, before the U.S. market open, on one of the busiest earnings days of the season and the morning after the U.S. midterm elections. The headline numbers beat expectations on both the top and bottom lines:

Revenue: $108.4 billion, up 5.4% from a year ago, beating the roughly $104.7 billion consensus by about $3.7 billion.
Adjusted EPS: $2.09, up from $1.60 a year earlier and $0.44 above the $1.65 consensus estimate.
GAAP EPS: $1.68, swinging from a loss of $3.13 per share in the same quarter last year.
Operating cash flow: $15.3 billion generated in the first nine months of 2026.

The year-ago loss was not an operating collapse: it reflected a $5.7 billion goodwill impairment charge recorded in the third quarter of 2025. Strip that out, and the story of this quarter is a genuine improvement in profitability, not just an easy comparison.

Why it's blowing up

The beat is so large because the driver is the part of CVS investors worried about most: its health insurance business. The Health Care Benefits segment, which includes Aetna, has been working through a margin recovery plan after a stretch of elevated medical costs. This quarter, that plan showed up in the numbers. Adjusted operating income for the segment improved by about $598 million, its medical benefit ratio fell 150 basis points to 91.3%, and adjusted operating income nearly tripled year over year. Across the whole company, adjusted operating income rose 21.2%.

Then management raised the outlook. Full-year 2026 adjusted EPS guidance rose to at least $8.20, up from $7.90 to $8.10 — a floor above the old ceiling. GAAP EPS guidance moved to at least $6.98, and the operating cash flow target jumped to at least $15.5 billion from at least $11.5 billion.

The timing adds to the attention. CVS reported hours after Democrats swept both chambers of Congress in the midterm elections, a result that puts health policy — including Medicaid and Medicare spending — back at the center of the Washington debate. CVS is one of the companies most exposed to that debate, which is why its earnings call and any commentary on policy are being watched closely today.

The key facts at a glance

Q3 2026 revenue: $108.4 billion, up 5.4% year over year.
Q3 adjusted EPS: $2.09 vs. $1.65 expected; Q3 GAAP EPS: $1.68 vs. a $3.13 loss a year ago.
Full-year 2026 guidance raised: adjusted EPS at least $8.20; GAAP EPS at least $6.98; operating cash flow at least $15.5 billion.
Health Care Benefits margin recovery: medical benefit ratio 91.3%, down 150 basis points year over year.
Year-to-date operating cash flow: $15.3 billion.
CVS shares closed Tuesday at $91.41, up about 3.3% on the day, ahead of the report.

What's next

Three things will decide whether this beat holds its value. First, the earnings call: investors will press management on whether the insurance margin recovery can continue into the fourth quarter, given that CVS itself flagged continued elevated cost trends and potential macroeconomic headwinds. Second, the policy backdrop: a Democratic-controlled Congress could push to reverse recent Medicaid and Medicare cuts, which would matter directly for CVS's benefits business. Third, the rest of the week: Friday's nonfarm payrolls report will shape expectations for the Federal Reserve's next move, and that backdrop affects the whole health care sector.

CVS raised guidance while explicitly keeping a cautious view for the remainder of the year — a big beat, a higher guide, and a warning not to extrapolate too fast. This article reports what happened and why markets reacted; it is not investment advice.

Sources

Frequently asked questions

Did CVS Health beat earnings expectations?

Yes. CVS reported adjusted EPS of $2.09 for Q3 2026, beating the $1.65 consensus estimate by $0.44, with revenue of $108.4 billion beating the roughly $104.7 billion expected.

Why did CVS Health raise its guidance?

Management cited improved expectations in its Health Care Benefits and Pharmacy & Consumer Wellness segments, driven by the insurance margin recovery plan, and raised full-year adjusted EPS guidance to at least $8.20.

What drove the profit improvement?

The Health Care Benefits segment led the way: its medical benefit ratio fell 150 basis points to 91.3% and its adjusted operating income improved by about $598 million as the margin recovery plan took hold.

Is there a catch in the report?

Yes, a note of caution. CVS kept a cautious view for the rest of the year, citing continued elevated cost trends and potential macroeconomic headwinds, even as it raised its guidance.